The role of paclitaxel in chemosensitive urological malignancies: Current strategies in bladder cancer and testicular germ-cell tumors

World Journal of Urology

Volumn 14, Issue 6, 1996, Pages 354-359

  Bokemeyer, C ^a   Hartmann, J T ^a   Kuczyk, M A ^a   Truss, M C ^b   Beyer, J ^b   Jonas, U ^b   Kanz, L ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

BLADDER TUMOR; GERM CELL TUMOR; HUMAN; MALE; REVIEW; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GERMINOMA; HUMANS; MALE; PACLITAXEL; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0030341774     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00183114     Document Type: Article

References (37)

1. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn L, Siegert W (1996) High-dose chemotherapy (HDCT) as salvage treatment in germ cell tumors (GCT): a multivariate analysis of prognostic variables (abstract 593). Proc Am Soc Clin Oncol 15:239
2. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 120:754-757
3. Bokemeyer C, Beyer J, Rüher U, Harstrick A, Weißbach L, Köhrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31-34
4. Chao CCK, Lee YL, Cheng PW, Chao SL (1991) Enhanced host cell reactivation of damaged plasmid DNA in HeLA cells resistant to r/s-diamminedichloroplatinum(II). Cancer Res 51 : 601-605
5. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524
6. Christou A, Roth B, Fox S, Williams S, Nichols C, Loehrer P, Buday M, Einhorn L (1996) Phase II trial of paclitaxel in refractory germ cell neoplasms (abstract 632). Proc Am Soc Clin Oncol 15:249
7. Crawford ED, Saiers JH, Baker LH, Costanzi JH, Bukowski RM (1991) Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. Urology 38:355-357
8. Dreicer R, Gustin D, See WA, Williams RD (1996) Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy (abstract 607). Proc Am Soc Clin Oncol 15:242
9. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8:1777-1781
10. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422
11. Harker WG, Meyers JF, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J Clin Oncol 3:1463-1470
12. Herr HW, Scher HI (1994) Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12: 975-980
13. Hill BT, Shellard SA, Whelan RDH, Fera MF, Harstrick A, Fichtinger-Schepman AJ (1992) Deficient removal of the major platinum-DNA intrastrand crosslinks in the sequences pGpG and pApG appears characteristic of testicular teratoma cell lines derived from tumours from untreated patients and may account for their sensitivity to cisplatin (abstract 221). Proc Am Soc Oncol 11:100
14. Hillcoat BL, Raghavan D, Matthews J, Kefford R, Yuen K, Woods R. Olver I, Bishop J, Pearson B, Coorey G, et al. (1989) A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7 : 706-709
15. Kaufman DS, Shipley WU. Griffin PP, Heney NM, Althausen AF, Efird JT (1993) Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329 : 1377-1382
16. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, et al. (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24
17. McCaffrcy J, Hilton S, Mazumdar M, Spicer J, Meegan G, Kelly K, Scher H, Bajorin D (1996) A phase II trial of ifosfamide, paclitaxel and cisplatin (ITP) in patients (pts) with advanced urothelial tract tumors (abstract 641). Proc Am Soc Clin Oncol 125:251
18. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 11 1 : 273-279
19. Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI. Lyn P, Fischer P (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283
20. Motzer RJ. Chou TC, Schwartz LH. Bosl GJ, Bajorin DF, Hutter H (1995) Paclitaxel in germ cell cancer. Semin Oncol 22 [Suppl6]:12-15
21. Murphy BA, Johnson DR, Smith J, Koch M, DeVore R, Blanke C, Johnson DH (1996) Phase II trial of paclitaxel (P) and cisplatin (C) for métastases of locally unresectable urothelial cancer (abstract 617). Proc Am Soc Clin Oncol 15:245
22. Nichols C, Tricot G, Williams S, Besien K van, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R. Wolff SN, et al. (1989) Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932-939
23. Niell HB, Rangel C, Miller A, Cox C (1993) The activity of antimicrotubular agents in human bladder tumor cell lines (abstract). Proc Am Assoc Cancer Res 34:202
24. Partyka S, Hutchinson L, Amato R (1996) Preliminary results of taxol/cisplatin chemotherapy in patients with refractory or relapsed nonseminomatous germ cell tumor (abstract 1161). Proc Am Assoc Cancer Res 37: 169
25. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V. Hudis ÇA, et al. (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. 3 Clin Oncol 11:1943-1951
26. Roth BJ, Bajorin DF (1995) Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153:894-900
27. Roth B, Dreicer R, Einhorn LH, Neuber D, Johnson DH, Smith JL, Hudes GR, Schultz M, Loehrer PJ (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270
28. Rowinsky EK, Gilbert MR, MeGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, et al. (1991) Sequences of taxol and cisplatin: a phase I and pharmacologie study. J Clin Oncol 9: 1692-1703
29. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SO, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 4 [Suppl 3): 1-15
30. Scher HI, Norton L (1992) Chemotherapy for urothelial tract malignancies. Semin Surg Oncol 8:316-341
31. Scher HI, Geller NL, Curley T, Tao Y ( 1993) Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 11:400-407
32. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:655-667
33. Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y, et al. (1993) Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 408-14
34. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D (1994) High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 12:1223-1231
35. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC. Vaughan ED, Bander N, et al. (1989) Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64:2448-2458
36. Tu S, Hossan E, Amato R, Kilbourn R, Logothetis CJ (1995) Paclitaxel, cisplatin and methotrexate combination therapy is active in the treatment of refractory urothelial malignancies. JUrol 154:1719-1722
37. Vaughn DJ, Malkowicz SB, Zoltick B, Ramchandani P, Tonkonow B, Fox K, Armstead B, Wein A (1996) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: a well-tolerated outpatient regimen (abstract 597). Proc Am Soc Clin Oncol 15:240